摘要
背景与目的:淋巴瘤是最常见的淋巴造血系统恶性肿瘤,其中B细胞型非霍奇金淋巴瘤(non-Hodgkin’s lymphoma,NHL)发病占淋巴瘤的90%以上,而NHL中最常见的亚型为弥漫大B细胞淋巴瘤(diffuselargeB-cell lymphoma,DLBCL)。探讨钙网蛋白(calreticulin)在DLBCL中的表达及其临床意义。方法:应用免疫组织化学染色,检测复旦大学附属中山医院2015-2018年收治的143例DLBCL患者肿瘤组织中calreticulin等蛋白的表达情况,并分析calreticulin表达与DLBCL患者临床病理学特征及预后的关系。结果:143例DLBCL患者中,calreticulin阳性表达者92例,阳性表达率为64.3%。Calreticulin阳性组死亡患者的比例(26.1%)明显高于calreticulin阴性组(9.8%),差异有统计学意义(χ2=5.381,P=0.020)。Kaplan-Meier生存曲线显示,calreticulin阳性表达组较阴性表达组生存期短(χ2=5.285,P=0.022)。结论:DLBCL患者中,calreticulin表达与DLBCL预后密切相关,检测calreticulin的表达可以作为判断DLBCL预后的依据之一。
Background and purpose: Lymphoma is the most common hematopoietic malignant tumor. B-cell non-Hodgkin’s lymphoma(NHL) accounts for more than 90% of lymphomas. The most common subtype in B-cell NHL is diffuse large B-cell lymphoma(DLBCL). This study aimed to investigate the expression of calreticulin in DLBCL and its clinical significance. Methods: Immunohistochemical staining was used to detect the expression of calreticulin and other proteins in tumor tissues of 143 DLBCL patients treated in Zhongshan Hospital, Fudan University from 2015 to 2018. Association between the expression of calreticulin and the clinicopathologic characteristics and prognosis of DLBCL patients was analysed. Results: Among 143 DLBCL patients, 92 were positive for calreticulin, and the positive expression rate was 64.3%. The proportion of death in the calreticulin positive group(26.1%) was significantly higher than that in the calreticulin negative group(9.8%), and the difference was statistically significant(χ2=5.381, P=0.020). Kaplan-Meier survival curve showed that the calreticulin positive group had a shorter survival time than the negative group(χ2=5.285, P=0.022). Conclusion: In DLBCL patients, expression level of calreticulin was closely related to prognosis of DLBCL patients. Calreticulin can be used as one of the indicators of clinical prognosis evaluation.
作者
葛晓雯
姚家美
朱娜
栾丽娟
高峰
曾海英
纪元
谭云山
侯英勇
GE Xiaowen;YAO Jiamei;ZHU Na;LUAN Lijuan;GAO Feng;ZENG Haiying;JI Yuan;TAN Yunshan;HOU Yingyong(Department of Pathology,Zhongshan Hospital,Fudan University,Shanghai 200032,China)
出处
《中国癌症杂志》
CAS
CSCD
北大核心
2020年第5期347-354,共8页
China Oncology
基金
国家自然科学基金青年基金(81402570)
上海市临床重点专科(shslczdzk01302)。
